Jan 16, 2026 | Press Releases
Durable complete responses with CAR-NK + Rituximab in patients who failed current standards of care in Waldenstrom’s Non-Hodgkins lymphoma (NHL). Long-term evaluable patients demonstrate ongoing complete response of 7 and 15 months after receiving a total...
Jan 16, 2026 | Press Releases
Enrollment of BCG naïve subjects (QUILT-2.005) receiving BCG alone versus BCG plus ANKTIVA exceeding expectations 85% enrolled with anticipated completion in Q2 2026 with BLA filing to U.S. Food and Drug Administration (FDA) by year end Interim analysis requested by...
Jan 15, 2026 | Press Releases
ANKTIVA® sales momentum continues to trend upward with full year preliminary net product revenue of approximately $113.0 million, a ~700% increase year over year The three-month period ending December 31, 2025, preliminary net product revenue of approximately...
Jan 14, 2026 | Press Releases
ANKTIVA, in combination with an immune checkpoint inhibitor, has received accelerated approval from the Saudi Food and Drug Authority for the treatment of metastatic non-small cell lung cancer, marking the first approval in the world of a subcutaneously administered...
Jan 14, 2026 | Press Releases
Approval of ANKTIVA was granted for BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ, with or without papillary disease, based on review of data from QUILT-3.032 Adding to existing ANKTIVA NMIBC approvals in the U.S. and U.K., and...
Jan 13, 2026 | Press Releases
ANKTIVA® plus checkpoint inhibitor (CPI) therapy demonstrated statistically significant immune restoration across two clinical trials in 151 patients with non-small cell lung cancer (NSCLC) In first-line NSCLC (QUILT-2.023), a randomized study demonstrated a...
